A detailed history of Prosight Management, LP transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Prosight Management, LP holds 3,022,109 shares of CTMX stock, worth $3.23 Million. This represents 0.96% of its overall portfolio holdings.

Number of Shares
3,022,109
Holding current value
$3.23 Million
% of portfolio
0.96%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.12 - $1.51 $3.38 Million - $4.56 Million
3,022,109 New
3,022,109 $3.57 Million

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $70.6M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Prosight Management, LP Portfolio

Follow Prosight Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Prosight Management, LP with notifications on news.